Saturday, February 17, 2024 10:02:02 AM
MAIA........................................https://stockcharts.com/h-sc/ui?s=MAIA&p=W&b=5&g=0&id=p86431144783
Recent MAIA News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2026 10:03:29 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/19/2026 10:15:02 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2026 09:02:35 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/14/2026 09:00:12 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/11/2026 01:00:49 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/27/2026 10:05:19 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/16/2026 01:25:30 PM
- MAIA Biotechnology Activates First U.S. Site for Ongoing International Phase 2 Expansion Trial of Novel Telomere Targeting Treatment Targeting Advanced Non-Small Cell Lung Cancer • GlobeNewswire Inc. • 04/16/2026 01:20:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/14/2026 12:44:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/14/2026 12:42:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/08/2026 01:10:06 PM
- MAIA Biotechnology Expects Recent $33 Million Capital Raise to Fully Fund Ongoing Pivotal Phase 3 Trial of Novel Telomere-Targeting Anticancer Therapy • GlobeNewswire Inc. • 04/08/2026 01:00:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 04/07/2026 09:19:51 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/07/2026 01:15:28 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/07/2026 01:04:09 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/07/2026 01:02:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:55:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:53:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:51:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:50:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:48:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 08:15:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/31/2026 01:25:17 PM
- MAIA Biotechnology Reports Overall Survival Exceeding Two Years for Eight Patients in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer • GlobeNewswire Inc. • 03/31/2026 01:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 12:00:30 PM
